Immitra Bio is a startup based in Switzerland, 1 tracked investor.
Based in Switzerland, Immitra Bio is a startup. Brouky records 1 investor associated with the company.
Immitra Bio is a spin-off from ETH Zurich developing a next-generation platform for in vivo gene editing to treat rare genetic disorders. The company aims to deliver off-the-shelf, single-injection gene therapies that correct genetic defects directly in the body as an alternative to highly personalized ex vivo approaches.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.